** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences GILD.O lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.
** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEG
EXPECTING STRONG UPTAKE IN 2026
** J.P.Morgan ("overweight") continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing
** Mizuho ("outperform", PT:$117) says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers
** Oppenheimer ("outperform", PT:$125) thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential
** TD Cowen ("buy", PT:$110) sees multi-billion dollar peak sales potential for Yeztugo and says patient adherence to GILD's drug will be around 80% compared to 50% to 55% adherence rate seen with daily oral therapies
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.